Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Central SELENOT deficiency impairs gonadotrope axis function, sexual behavior, and fertility in male and female mice
Ben Yamine Mallouki, Loubna Boukhzar, Ludovic Dumont, Azénor Abgrall, Marjorie Gras, Agathe Prieur, David Alexandre, David Godefroy, Yves Tillet, Nathalie Rives, Luca Grumolato, Fatiha Chigr, Youssef Anouar
Ben Yamine Mallouki, Loubna Boukhzar, Ludovic Dumont, Azénor Abgrall, Marjorie Gras, Agathe Prieur, David Alexandre, David Godefroy, Yves Tillet, Nathalie Rives, Luca Grumolato, Fatiha Chigr, Youssef Anouar
View: Text | PDF
Research Article Endocrinology Reproductive biology

Central SELENOT deficiency impairs gonadotrope axis function, sexual behavior, and fertility in male and female mice

  • Text
  • PDF
Abstract

Reproductive disorders can result from a defective action of the neuropeptide gonadotropin-releasing hormone (GnRH), the master regulator of reproduction. We have previously shown that selenoprotein T (SELENOT), a newly described thioredoxin-like selenoprotein highly expressed in endocrine and neuroendocrine cells, plays a role in hormone secretion and neuroprotection. However, whether SELENOT is involved in neuroendocrine regulation in vivo is totally unknown. We found that SELENOT deficiency in the brain impaired sexual behavior, leading to a decline in fertility in both male and female mice. Biochemical and histological analyses of the gonadotrope axis of these mice revealed a higher expression of GnRH, which is associated with circulating luteinizing hormone (LH) excess, and elevated steroid hormones in males and a polycystic ovary syndrome–like phenotype in females. In addition, SELENOT deficiency impaired LH pulse secretion in both male and female mice. These changes were reverted after administration of a GnRH antagonist. Together, our data demonstrate for the first time to our knowledge the role of a selenoprotein in the central control of sexual behavior and reproduction, and identify a redox effector of GnRH neuron activity impacting both male and female reproductive function.

Authors

Ben Yamine Mallouki, Loubna Boukhzar, Ludovic Dumont, Azénor Abgrall, Marjorie Gras, Agathe Prieur, David Alexandre, David Godefroy, Yves Tillet, Nathalie Rives, Luca Grumolato, Fatiha Chigr, Youssef Anouar

×

Figure 7

Treatment with a GnRH antagonist restored the neuroendocrine phenotype of female brain SELENOT–deficient mice.

Options: View larger image (or click on image) Download as PowerPoint
Treatment with a GnRH antagonist restored the neuroendocrine phenotype o...
(A) Schematic of the experimental design showing the 3 steps of the protocol, before, during, and after i.p. injection of 0.5 mg/kg of cetrorelix acetate or PBS. Female Nes-Cre:Selenotfl/fl mice were injected i.p. for 12 days with cetrorelix acetate (every other day). Tail blood samples were collected for measurement of LH, once before the start of the treatment and then on days 2 and 6 of treatment, as well as on day 4 after the last injection (n = 5 per group). (B) Time course of serum LH concentration in Nes-Cre:Selenotfl/fl mice before the beginning of the treatment, 2 and 6 days after the first injection of cetrorelix, and after discontinuation of the drug antagonist. Blood from control and Nes-Cre:Selenotfl/fl mice that received PBS injection as a control was collected during the same temporal windows as for cetrorelix treatment. (C–E) Percentage of time spent in each estrous cycle was determined for each group of animals and in each condition (E, estrus; M/D, metestrus/diestrus; P, proestrus). Statistical analysis was performed using the nonparametric Kruskal-Wallis test with a post hoc Dunn’s test. *P < 0.05; **P < 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts